Publikation:

Insights into incretin-based therapies for treatment of diabetic dyslipidemia

Vorschaubild

Dateien

Zu diesem Dokument gibt es keine Dateien.

Datum

2020

Autor:innen

Finan, Brian
DiMarchi, Richard D.
Tschöp, Matthias H.
Müller, Timo D.

Herausgeber:innen

Kontakt

ISSN der Zeitschrift

Electronic ISSN

ISBN

Bibliografische Daten

Verlag

Schriftenreihe

Auflagebezeichnung

URI (zitierfähiger Link)
DOI (zitierfähiger Link)
https://doi.org/10.1016/j.addr.2020.05.008
ArXiv-ID

Internationale Patentnummer

Angaben zur Forschungsförderung

Projekt

Open Access-Veröffentlichung

Sammlungen

Biologie: Publikationen
Core Facility der Universität Konstanz

Gesperrt bis

Titel in einer weiteren Sprache

Publikationstyp
Zeitschriftenartikel
Publikationsstatus
Published

Erschienen in

Advanced Drug Delivery Reviews. Elsevier. 2020, 159, pp. 34-53. ISSN 0169-409X. eISSN 1872-8294. Available under: doi: 10.1016/j.addr.2020.05.008

Zusammenfassung

Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.

Zusammenfassung in einer weiteren Sprache

Fachgebiet (DDC)
570 Biowissenschaften, Biologie

Schlagwörter

Incretins; Lipoproteins; Dyslipidemia; Diabetes; Obesity

Konferenz

Rezension
undefined / . - undefined, undefined

Forschungsvorhaben

Organisationseinheiten

Zeitschriftenheft

Zugehörige Datensätze in KOPS

Zitieren

ISO 690STEMMER, Kerstin, Brian FINAN, Richard D. DIMARCHI, Matthias H. TSCHÖP, Timo D. MÜLLER, 2020. Insights into incretin-based therapies for treatment of diabetic dyslipidemia. In: Advanced Drug Delivery Reviews. Elsevier. 2020, 159, pp. 34-53. ISSN 0169-409X. eISSN 1872-8294. Available under: doi: 10.1016/j.addr.2020.05.008
BibTex
@article{Stemmer2020Insig-52377,
  year={2020},
  doi={10.1016/j.addr.2020.05.008},
  title={Insights into incretin-based therapies for treatment of diabetic dyslipidemia},
  volume={159},
  issn={0169-409X},
  journal={Advanced Drug Delivery Reviews},
  pages={34--53},
  author={Stemmer, Kerstin and Finan, Brian and DiMarchi, Richard D. and Tschöp, Matthias H. and Müller, Timo D.}
}
RDF
<rdf:RDF
    xmlns:dcterms="http://purl.org/dc/terms/"
    xmlns:dc="http://purl.org/dc/elements/1.1/"
    xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
    xmlns:bibo="http://purl.org/ontology/bibo/"
    xmlns:dspace="http://digital-repositories.org/ontologies/dspace/0.1.0#"
    xmlns:foaf="http://xmlns.com/foaf/0.1/"
    xmlns:void="http://rdfs.org/ns/void#"
    xmlns:xsd="http://www.w3.org/2001/XMLSchema#" > 
  <rdf:Description rdf:about="https://kops.uni-konstanz.de/server/rdf/resource/123456789/52377">
    <dcterms:isPartOf rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dc:creator>Müller, Timo D.</dc:creator>
    <dc:creator>DiMarchi, Richard D.</dc:creator>
    <dcterms:available rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dcterms:available>
    <dcterms:title>Insights into incretin-based therapies for treatment of diabetic dyslipidemia</dcterms:title>
    <dc:language>eng</dc:language>
    <dc:contributor>Tschöp, Matthias H.</dc:contributor>
    <dspace:isPartOfCollection rdf:resource="https://kops.uni-konstanz.de/server/rdf/resource/123456789/28"/>
    <dcterms:issued>2020</dcterms:issued>
    <dc:date rdf:datatype="http://www.w3.org/2001/XMLSchema#dateTime">2021-01-13T10:53:47Z</dc:date>
    <dc:contributor>Stemmer, Kerstin</dc:contributor>
    <dc:contributor>DiMarchi, Richard D.</dc:contributor>
    <dcterms:abstract xml:lang="eng">Derangements in triglyceride and cholesterol metabolism (dyslipidemia) are major risk factors for the development of cardiovascular diseases in obese and type-2 diabetic (T2D) patients. An emerging class of glucagon-like peptide-1 (GLP-1) analogues and next generation peptide dual-agonists such as GLP-1/glucagon or GLP-1/GIP could provide effective therapeutic options for T2D patients. In addition to their role in glucose and energy homeostasis, GLP-1, GIP and glucagon serve as regulators of lipid metabolism. This review summarizes the current knowledge in GLP-1, glucagon and GIP effects on lipid and lipoprotein metabolism and frames the emerging therapeutic benefits of GLP-1 analogs and GLP-1-based multiagonists as add-on treatment options for diabetes associated dyslipidemia.</dcterms:abstract>
    <bibo:uri rdf:resource="https://kops.uni-konstanz.de/handle/123456789/52377"/>
    <dc:creator>Finan, Brian</dc:creator>
    <void:sparqlEndpoint rdf:resource="http://localhost/fuseki/dspace/sparql"/>
    <dc:contributor>Finan, Brian</dc:contributor>
    <dc:contributor>Müller, Timo D.</dc:contributor>
    <dc:creator>Stemmer, Kerstin</dc:creator>
    <dc:creator>Tschöp, Matthias H.</dc:creator>
    <foaf:homepage rdf:resource="http://localhost:8080/"/>
  </rdf:Description>
</rdf:RDF>

Interner Vermerk

xmlui.Submission.submit.DescribeStep.inputForms.label.kops_note_fromSubmitter

Kontakt
URL der Originalveröffentl.

Prüfdatum der URL

Prüfungsdatum der Dissertation

Finanzierungsart

Kommentar zur Publikation

Allianzlizenz
Corresponding Authors der Uni Konstanz vorhanden
Internationale Co-Autor:innen
Universitätsbibliographie
Ja
Begutachtet
Ja
Diese Publikation teilen